{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:13:19Z","timestamp":1790089999147,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Association of Rehabilitation Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13555-025-01540-w","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:49:34Z","timestamp":1758268174000},"page":"3377-3389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The ChinaSTAD Chinese Registry in Patients with Moderate-To-Severe Atopic Dermatitis Not Controlled by Topical Therapy: Baseline Characteristics, Disease Burden and Treatment"],"prefix":"10.1007","volume":"15","author":[{"given":"Ping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-682X","authenticated-orcid":false,"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"1540_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384:1136\u201343.","journal-title":"N Engl J Med"},{"key":"1540_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/JD9.0000000000000143","volume":"4","author":"X Yao","year":"2021","unstructured":"Yao X, Song Z-Q, Li W, et\u00a0al. Guidelines for diagnosis and treatment of atopic dermatitis in China (2020). Int J Dermatol Venereol. 2021;4:1\u20139.","journal-title":"Int J Dermatol Venereol"},{"key":"1540_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100604","volume":"14","author":"W-l Dong","year":"2021","unstructured":"Dong W-l, An J, Yu M, et\u00a0al. The prevalence and year lived with disability of atopic dermatitis in China: findings from the global burden of disease study 2019. World Allergy Organ J. 2021;14:100604.","journal-title":"World Allergy Organ J"},{"key":"1540_CR4","volume":"6","author":"CH Na","year":"2019","unstructured":"Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel). 2019;6:133.","journal-title":"Children (Basel)"},{"key":"1540_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et\u00a0al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1540_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/1346-8138.15048","volume":"46","author":"TF Tsai","year":"2019","unstructured":"Tsai TF, Rajagopalan M, Chu CY, et\u00a0al. Burden of atopic dermatitis in Asia. J Dermatol. 2019;46:825\u201334.","journal-title":"J Dermatol"},{"key":"1540_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4103\/0366-6999.178960","volume":"129","author":"P Liu","year":"2016","unstructured":"Liu P, Zhao Y, Mu ZL, et\u00a0al. Clinical features of adult\/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis. Chin Med J (Engl). 2016;129:757\u201362.","journal-title":"Chin Med J (Engl)"},{"key":"1540_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/CM9.0000000000002560","volume":"136","author":"D Mao","year":"2023","unstructured":"Mao D, Li J, Liu S, et\u00a0al. Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study. Chin Med J (Engl). 2023;136:604\u20136.","journal-title":"Chin Med J (Engl)"},{"key":"1540_CR9","doi-asserted-by":"publisher","first-page":"2568301","DOI":"10.1155\/2016\/2568301","volume":"2016","author":"X Wang","year":"2016","unstructured":"Wang X, Li LF, Zhao DY, et\u00a0al. Prevalence and clinical features of atopic dermatitis in China. Biomed Res Int. 2016;2016:2568301.","journal-title":"Biomed Res Int"},{"key":"1540_CR10","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0140-6736(05)65466-9","volume":"348","author":"HC Williams","year":"1996","unstructured":"Williams HC. Diagnostic criteria for atopic dermatitis. Lancet. 1996;348:1391\u20132.","journal-title":"Lancet"},{"key":"1540_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000247298","volume":"186","author":"European Task Force on Atopic Dermatitis","year":"1993","unstructured":"European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23\u201331.","journal-title":"Dermatology"},{"key":"1540_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140:1513\u20139.","journal-title":"Arch Dermatol"},{"key":"1540_CR13","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjd.12590","volume":"169","author":"CR Charman","year":"2013","unstructured":"Charman CR, Venn AJ, Ravenscroft JC, et\u00a0al. Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169:1326\u201332.","journal-title":"Br J Dermatol"},{"key":"1540_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et\u00a0al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181:761\u20139.","journal-title":"Br J Dermatol"},{"key":"1540_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, et\u00a0al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36:367\u201376.","journal-title":"Curr Med Res Opin"},{"key":"1540_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-019-0095-3","volume":"19","author":"E Simpson","year":"2019","unstructured":"Simpson E, Eckert L, Gadkari A, et\u00a0al. Validation of the Atopic Dermatitis Control Tool (ADCT\u00a9) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19:15.","journal-title":"BMC Dermatol"},{"key":"1540_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1540_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132:942\u20139.","journal-title":"Br J Dermatol"},{"key":"1540_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, et\u00a0al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125:659\u201364.","journal-title":"J Invest Dermatol"},{"key":"1540_CR20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bjd.14361","volume":"174","author":"JR Olsen","year":"2016","unstructured":"Olsen JR, Gallacher J, Finlay AY, et\u00a0al. Quality of life impact of childhood skin conditions measured using the Children\u2019s Dermatology Life Quality Index (CDLQI): a meta-analysis. Br J Dermatol. 2016;174:853\u201361.","journal-title":"Br J Dermatol"},{"key":"1540_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/CM9.0000000000003042","volume":"138","author":"J Zhao","year":"2024","unstructured":"Zhao J, Zhang Z, Chen H, et\u00a0al. Associations of demographics, aggravating factors, comorbidities, and treatments with atopic dermatitis severity in China: a national cross-sectional study. Chin Med J (Engl). 2024;138:553\u201361.","journal-title":"Chin Med J (Engl)"},{"key":"1540_CR22","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s13555-024-01244-7","volume":"14","author":"CY Chu","year":"2024","unstructured":"Chu CY, Chan Y, Wananukul S, et\u00a0al. Quality of life and burden of moderate-to-severe atopic dermatitis in adult patients within the Asia-Pacific region: a cross-sectional survey. Dermatol Ther (Heidelb). 2024;14:2479\u201393.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1540_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y, et\u00a0al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190:55\u201361.","journal-title":"Br J Dermatol"},{"key":"1540_CR24","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, et\u00a0al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1540_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","volume":"8","author":"AB Fishbein","year":"2020","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ, et\u00a0al. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91\u2013101.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1540_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165370","volume":"12","author":"C Gu","year":"2023","unstructured":"Gu C, Yao X, Li W. Burden of disease; the current status of the diagnosis and management of atopic dermatitis in China. J Clin Med. 2023;12:5370.","journal-title":"J Clin Med"},{"key":"1540_CR27","unstructured":"Sanofi. Dupixent\u00ae (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis [press release]. 2020. Sanofi. https:\/\/www.sanofi.com\/en\/media-room\/press-releases. Accessed 19 May 2023."},{"key":"1540_CR28","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1007\/s13555-022-00816-9","volume":"12","author":"C-H Tang","year":"2022","unstructured":"Tang C-H, Huang Y-H, Chuang P-Y, et\u00a0al. Patient characteristics, treatment patterns, healthcare resource utilization, and costs of targeted therapy-eligible atopic dermatitis patients in Taiwan\u2014a real-world study. Dermatol Ther. 2022;12:2547\u201362.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01540-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01540-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01540-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:17:51Z","timestamp":1761239871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01540-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01540-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jianzhong Zhang is a consultant for and has received honoraria from Pfizer Investment Co Ltd, Novartis Pharmaceuticals (China), Sanofi China, LEO Pharma (Shanghai) Co Ltd, GSK (China) Investment Co Ltd, Eli Lilly and Company (China), Xi\u2019an Jassen Pharmaceutical Ltd, Bristol-Myers Squibb (China) Investment Co Ltd, Beijing Wenfeng Tianji Pharma Ltd, Keymed Biosciences (Chendu) Ltd, Akeso Biopharma Co Ltd, Reistone Biopharma Co Ltd and Kintor Pharmaceutical Ltd. Ping Liu, Bingjiang Lin, Yanna Shen, Yonghong Lu, Jingyi Li, Dong Lv, Xu Yao, Xiaoyong Man, Hong Fang, Guan Jiang, Nan Yu, Dongmei Liu and Siyan Zhan have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by the Ethics Committee of the Peking University People\u2019s Hospital (approval no. 2021PHB076-001; 7 April 2021) and the local ethics committees at other sites. The study was conducted in accordance with ethical principles that have their origins in the Declaration of Helsinki and that are consistent with International Conference on Harmonisation\/Good Clinical Practice, applicable regulatory requirements, and the sponsor\u2019s bioethics and human biospecimen policies. All patients or their legal guardians provided written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}